Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXT-MS
2024-513105-31-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Primary endpoint: Radiological disease activity after two years. Planned start Jul 2024; status: authorised.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-513105-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513105-31-00.